November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Oct 23, 2023, 15:26

Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)

Tom Powles, Director of Barts Cancer Centre, shared on Twitter:

Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached.

Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)

Tox was in line with expectations. Grade 3-5 TRAEs in 56% vs 70% for EVP and chemo respectively. 21% of EVP patients discontinuing for adverse events. G3+ skin tox and peripheral neuropathy occurred in 8% and 4% with no Grade 5. EVP tox is different from chemo but not worse.

Overall EVP looks transformative, superseding chemo/IO approaches. It’s attractive for patients and will hopefully get approved for use in the near future. Huge thanks to the research team and the patients.”

Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)

Source: Tom Powles/Twitter